Advertisement
Screener

Citius Pharmaceuticals, Inc. (CTXR) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

1.7 / 5 stars · 18/54 Roast Me

Citius Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

Citius Pharmaceuticals, Inc. (CTXR) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 11.73 million shares for the 12-month period ending 2023-09-30, per its 10-K filed 2023-12-29.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2023-12-29

  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-09-30 was 0.00 shares.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-06-30 was -75.00K shares.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-03-31 was 11.78M shares.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-12-31 was 35.00K shares, a 99.18% decline year-over-year.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 11.73M shares, a 202.06% increase from fiscal 2022.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 3.88M shares, a 48.41% decline from fiscal 2021.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 7.53M shares, a 205.48% increase from fiscal 2020.
  • Citius Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 2.46M shares, a 125.98% increase from fiscal 2019.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month
2023-09-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29
-75.00K shares
derived: sum of 2 quarters · filed 2023-12-29
11.70M shares
derived: sum of 3 quarters · filed 2023-12-29
11.73M shares
10-K · filed 2023-12-29
2023-06-30-75.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14
11.70M shares
derived: sum of 2 quarters · filed 2023-08-14
11.73M shares
10-Q · filed 2023-08-14
11.73M shares
derived: sum of 4 quarters · filed 2023-08-14
2023-03-3111.78M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12
11.81M shares
10-Q · filed 2023-05-12
11.81M shares
derived: sum of 3 quarters · filed 2023-05-12
11.73M shares
derived: sum of 4 quarters · filed 2023-05-12
2022-12-3135.00K shares
10-Q · filed 2023-02-10
35.00K shares
derived: sum of 2 quarters · filed 2023-02-10
-45.00K shares
derived: sum of 3 quarters · filed 2023-02-10
-345.00K shares
derived: sum of 4 quarters · filed 2023-02-10
2022-09-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22
-80.00K shares
derived: sum of 2 quarters · filed 2022-12-22
-380.00K shares
derived: sum of 3 quarters · filed 2022-12-22
3.88M shares
10-K · filed 2022-12-22
2022-06-30-80.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11
-380.00K shares
derived: sum of 2 quarters · filed 2022-08-11
3.88M shares
10-Q · filed 2022-08-11
2.79M shares
derived: sum of 4 quarters · filed 2022-08-11
2022-03-31-300.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12
3.96M shares
10-Q · filed 2022-05-12
2.87M shares
derived: sum of 3 quarters · filed 2022-05-12
10.26M shares
derived: sum of 4 quarters · filed 2022-05-12
2021-12-314.26M shares
10-Q · filed 2022-02-10
3.17M shares
derived: sum of 2 quarters · filed 2022-02-10
10.55M shares
derived: sum of 3 quarters · filed 2022-02-10
10.43M shares
derived: sum of 4 quarters · filed 2022-02-10
2021-09-30-1.10M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15
6.29M shares
derived: sum of 2 quarters · filed 2021-12-15
6.17M shares
derived: sum of 3 quarters · filed 2021-12-15
7.53M shares
10-K · filed 2021-12-15
2021-06-307.39M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12
7.26M shares
derived: sum of 2 quarters · filed 2021-08-12
8.63M shares
10-Q · filed 2021-08-12
8.01M shares
derived: sum of 4 quarters · filed 2021-08-12
2021-03-31-125.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-13
1.24M shares
10-Q · filed 2021-05-13
615.00K shares
derived: sum of 3 quarters · filed 2021-05-13
595.00K shares
derived: sum of 4 quarters · filed 2021-05-13
2020-12-311.36M shares
10-Q · filed 2021-02-11
740.00K shares
derived: sum of 2 quarters · filed 2021-02-11
720.00K shares
derived: sum of 3 quarters · filed 2021-02-11
3.72M shares
derived: sum of 4 quarters · filed 2021-02-11
2020-09-30-625.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-16
-645.00K shares
derived: sum of 2 quarters · filed 2020-12-16
2.35M shares
derived: sum of 3 quarters · filed 2020-12-16
2.46M shares
10-K · filed 2020-12-16
2020-06-30-20.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-14
2.98M shares
derived: sum of 2 quarters · filed 2020-08-14
3.09M shares
10-Q · filed 2020-08-14
3.09M shares
derived: sum of 4 quarters · filed 2020-08-14
2020-03-313.00M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-14
3.11M shares
10-Q · filed 2020-05-14
3.11M shares
derived: sum of 3 quarters · filed 2020-05-14
2.98M shares
derived: sum of 4 quarters · filed 2020-05-14
2019-12-31110.00K shares
10-Q · filed 2020-02-13
110.00K shares
derived: sum of 2 quarters · filed 2020-02-13
-15.00K shares
derived: sum of 3 quarters · filed 2020-02-13
-60.00K shares
derived: sum of 4 quarters · filed 2020-02-13
2019-09-300.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-16
-125.00K shares
derived: sum of 2 quarters · filed 2019-12-16
-170.00K shares
derived: sum of 3 quarters · filed 2019-12-16
1.09M shares
10-K · filed 2019-12-16
2019-06-30-125.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14
-170.00K shares
derived: sum of 2 quarters · filed 2019-08-14
1.09M shares
10-Q · filed 2019-08-14
2.35M shares
derived: sum of 4 quarters · filed 2019-08-14
2019-03-31-45.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15
1.22M shares
10-Q · filed 2019-05-15
2.48M shares
derived: sum of 3 quarters · filed 2019-05-15
2.48M shares
derived: sum of 4 quarters · filed 2019-05-15
2018-12-311.26M shares
10-Q · filed 2019-02-14
2.52M shares
derived: sum of 2 quarters · filed 2019-02-14
2.52M shares
derived: sum of 3 quarters · filed 2019-02-14
2.52M shares
derived: sum of 4 quarters · filed 2019-02-14
2018-09-301.26M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11
1.26M shares
derived: sum of 2 quarters · filed 2018-12-11
1.26M shares
derived: sum of 3 quarters · filed 2018-12-11
1.26M shares
10-K · filed 2018-12-11
2018-06-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14
0.00 shares
derived: sum of 2 quarters · filed 2018-08-14
799.00 shares
10-Q · filed 2018-08-14
-274.20K shares
derived: sum of 4 quarters · filed 2018-08-14
2018-03-310.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-11
799.00 shares
10-Q · filed 2018-05-11
-274.20K shares
derived: sum of 3 quarters · filed 2018-08-14
2017-12-31799.00 shares
10-Q · filed 2018-02-14
-274.20K shares
derived: sum of 2 quarters · filed 2018-08-14
2017-09-30-275.00K shares
derived: 10-Q 12 month − 10-Q 9 month · filed 2018-08-14
799.00 shares
10-Q · filed 2018-08-14
2017-06-30275.80K shares
10-Q · filed 2017-08-14
2016-09-30284.48K shares
10-Q · filed 2017-08-14
284.48K shares
10-K · filed 2017-12-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36